BARC Barclays PLC

Barclays Appoints Kieran Whitty as a Co-Head of Healthcare for Europe, Middle East and Africa

Barclays today announces the appointment of Kieran Whitty as Co-Head of Healthcare EMEA (Europe, Middle East and Africa), working alongside Sid Chhibbar, Co-Head of Healthcare EMEA.

This appointment reflects Barclays’ effort to continue its growth in the UK and Continental Europe, which is a key focus for Barclays investment bank.

Kieran joins Barclays from Bank of America where he spent 18 years, most recently as a Managing Director in the EMEA Healthcare team. He has a strong track record advising clients, with extensive experience and connections across the healthcare sector, specifically in the healthcare services and medtech space, working with corporates and sponsors. He recently advised PureHealth on its acquisition of Hellenic Healthcare Group and Nordic Capital on its exit from Sunrise Medical.

Kieran will work alongside Sid Chhibbar, who joined Barclays in 2015 and advises corporates and financial sponsors across the healthcare sector with a focus on Pharma and Pharma Services.

“Kieran’s extensive industry expertise and his proven track record in helping clients will be hugely complementary to our already strong healthcare practice,” said Richard Landgarten, Global Head of Healthcare and Real Estate. “We are delighted to be able to provide clients with expanded capabilities to support their growth.”

“Kieran’s appointment demonstrates our continued investment in senior talent and our commitment to helping clients,” said Alisdair Gayne, Co-Head of Investment Banking, EMEA. “It underlines the investment in our EMEA franchise to deepen relationships with our clients, whilst driving growth and delivering returns for our shareholders.”

Kieran joins in June and will be based in London, reporting to Richard Landgarten, Global Head of Healthcare and Real Estate Investment Banking.

About Barclays

Our vision is to be the UK-centred leader in global finance. We are a diversified bank with comprehensive UK consumer, corporate and wealth and private banking franchises, a leading investment bank and a strong, specialist US consumer bank. Through these five divisions, we are working together for a better financial future for our customers, clients and communities. For further information about Barclays, please visit our website .

EN
20/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Barclays PLC

Barclays: 2 directors

Two Directors at Barclays sold 56,700 shares at between 476p and 486p. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Barclays PLC: 2026-28 plan targets higher returns, but high Investment...

The plan features structurally stronger – but still below peers – profitability, disciplined risk-weighted asset deployment and stable capital.

Barclays PLC: 2025 financial guidance fully achieved, profitability re...

Barclays reported a modest revenue increase and flat costs while capital remained strong in the fourth quarter of 2025.

Barclays PLC: Update to credit analysis

Our credit view of this issuer reflects its good credit quality and risk-weighted capitalisation, against high exposure to confidence-sensitive and opaque capital markets activities.

Barclays PLC: Higher costs and increased credit impairments offset the...

Barclays reported strong revenue, but higher operating costs and high credit impairment charges in the third quarter of 2025.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch